
Cellectis Investor Relations Material
Latest events

Q3 2024
Cellectis
Access the full event backlog
Slides, Transcripts, and Reports from 12,000+ public companies
Latest reports from Cellectis S.A.
Access all reports
Cellectis is a clinical stage biotechnological company, developing immuno-oncology products based on gene-edited T-cells. According to Cellectis, it is one of the very few companies capable of generating next generation T-cell product candidates in an entirely novel approach. By combining the full functionality of T-cells with the specificity provided by artificial antigen receptors (chimeric antigen receptors), their program aims at achieving superior antiviral, anti-tumor and anti-inflammatory potential.
Key slides for Cellectis S.A.


Corporate Presentation
Cellectis S.A.


Corporate Presentation
Cellectis S.A.
Latest articles
)
Robert G. Hagstrom: Darwinian Investing and Multidisciplinary Wisdom
Robert G. Hagstrom, author of The Warren Buffett Way, explores how interdisciplinary thinking shapes his investing, from Adler's reading to Darwinian markets.
7 Feb 2025
)
Quartr Brings Stories Behind the Numbers to Light
Quartr simplifies access to IR material and puts qualitative insights and company narratives front and center.
3 Feb 2025
)
The Evolution of the IRO Role: Staying Informed and Strategic With Quartr Pro
Staying informed is critical for IROs. Quartr Pro simplifies gathering market insights and narrative positioning with unprecedented speed and precision.
3 Feb 2025
Ticker symbol
ALCLS
Country
🇫🇷 France